ASH 2024: Updates in the Treatment of CLL : Episode 2
Opinion
Video
ASH 2024 Updates: SEQUOIA 5-Year Follow-Up and Expert Perspectives in Selecting Between Acalabrutinib vs Zanubrutinib in TN CLL
Panelists discuss how long-term SEQUOIA trial data presented at ASH 2024 inform the selection between covalent BTK inhibitors zanubrutinib and acalabrutinib in treatment-naive CLL, including considerations for combining these agents with obinutuzumab.
Video content above is prompted by the following:
- SEQUOIA researchers presented their 5-year follow-up data at this year’s ASH 2024 — could you share key updates from their abstract as well as your impressions? Do these data influence your decision when selecting among the covalent BTKi in treatment-naive CLL?
- How do you decide between acala vs zanu? In which patients would you consider adding obinutuzumab?
Related Videos
Related Content
